We further characterized its prognostic role in core binding factor (CBF) AML in the context of established prognostic factors, as well as in intermediate-risk AML in the context of other mRNA expression prognostic factors (ERG, ID1, WT1, FLT3, WT1, BAALC, CDKN1B, MECOM/EVI1, MN1). The gene discussed is FLT3; the disease is acute myeloid leukemia.